The phrase "average vessel count" is correct and usable in written English.
It can be used in contexts related to statistics, biology, or any field where measuring the number of vessels (like blood vessels or shipping vessels) is relevant.
Example: "The average vessel count in the study group was significantly higher than in the control group."
Alternatives: "mean vessel count" or "typical vessel count".
Individual microvessels were then counted under a high power (×400) field to obtain a vessel count in a defined area, and the average vessel count in five hot spots was taken as the MVD.
The average vessel count of the five fields (×200) was regarded as the MVD.
Within the hot spot area, the stained microvessels were counted in a single high-power (200×) field, and the average vessel count in 3 hot spots was considered the value of MVD.
Individual microvessels were then counted under higher power (objective, × 40) to obtain a vessel count in a defined area, and the average vessel count in three hot spots was taken as the MVD.
Within the hot spot area, the stained microvessels were counted in a single high-power (200×) field, and the average vessel count in three hot spots was considered the value of MVD.
The average vessel counts with the four endothelial marker antibodies for normal control biopsies were compared to those counts from c-GVHD and SSc biopsies.
CD31-stained vessels were counted at 50× magnification at four different quadrants of each tumour (2 mm inside the tumour normal tissue interface), and average vessel counts were calculated.
Average CD31+ vessel counts were 62.3 per 0.45 mm2 section for Wnt1 tumors as compared to 25.3 for Her2 tumors (Fig. 1A).
The final microvessel score was the average of vessel counts from four fields.
The final microvessel score was the average of vessel counts from four fields assessed by a high power magnification field (×200).
At × 400 magnification, the average blood vessel counts per field (mean ± SD) were: 23.36 ± 5.56 blood microvessels in control tumors compared to 14.94 ± 3.79 for rapamycin-treated tumors (p < 0.0001; unpaired t test with Welch correction).
